Ursodeoxycholic acid (commercially available as Ursodiol) is a naturally occurring bile 25 acid that is used to treat a variety of hepatic and gastrointestinal diseases. Ursodiol can 26 modulate bile acid pools, which have the potential to alter the gut microbiota community 27 structure. In turn, the gut microbial community can modulate bile acid pools, thus 28 highlighting the interconnectedness of the gut microbiota-bile acid-host axis. Despite 29 these interactions, it remains unclear if and how exogenously administered ursodiol 30 shapes the gut microbial community structure and bile acid pool. This study aims to 31 characterize how ursodiol alters the gastrointestinal ecosystem in conventional mice. 32 C57BL/6J wildtype mice were given one of three doses of ursodiol (50, 150, or 450 33 mg/kg/day) by oral gavage for 21 days. Alterations in the gut microbiota and bile acids 34 were examined including stool, ileal, and cecal content. Bile acids were also measured 35 in serum. Significant weight loss was seen in mice treated with the low and high dose of 36 ursodiol. Alterations in the microbial community structure and bile acid pool were seen 37 in ileal and cecal content compared to pretreatment, and longitudinally in feces following 38 the 21-day ursodiol treatment. In both ileal and cecal content, members of the 39
Introduction 63
Bile acids are produced by host hepatocytes from cholesterol and are released into the 64 gastrointestinal tract where they aid in the emulsification and absorption of dietary fat. 65
Once host derived primary bile acids, namely cholic acid (CA) and chenodeoxycholic 66 acid (CDCA) in humans, enter into the gastrointestinal tract the indigenous gut 67 microbiota transforms them into secondary bile acids. 1, 2 Over 50 chemically distinct 68 microbial derived secondary bile acids have been identified. 2 Both primary and 69 secondary bile acids can act as signaling molecules, exerting their effects by activating 70 bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5) 71 and the farnesoid X receptor (FXR). [3] [4] [5] Examination of the gut microbiota-bile acid-host 72 axis is growing in diverse fields including gastroenterology, endocrinology, oncology, 73 immunology, and infectious disease. 1,3-13 74 Ursodeoxycholic acid (UDCA) is a bile acid that has been medicinally utilized for 75 over 2500 years. 14 In humans, UDCA is considered a secondary bile acid derived from 76 microbial conversion of the primary bile acid CDCA into lithocholic acid (LCA) and then 77 into UDCA. 15 However in other species, including mice, UDCA is a considered a host 78 derived primary bile acid. [16] [17] [18] The Food and Drug Administration (FDA) approved 79 formulation of UDCA, or ursodiol, is used to treat a variety of diseases including: 80 cholesterol gallstones, primary biliary cirrhosis, primary sclerosing cholangitis, non-81 alcoholic fatty liver disease, chronic viral hepatitis C, recurrent colonic adenomas, 82 cholestasis of pregnancy, and recurrent pancreatitis. 6, [19] [20] [21] [22] [23] [24] [25] [26] [27] Ursodiol has vast beneficial 83 effects (antichloestatic, antifibrotic, antiproliferative, and anti-inflammatory) but the major 84 effect on bile acid physiology is an increase in hydrophilic bile acid pool by diluting the 85 concentration of the hydrophobic toxic secondary bile acids, deoxycholic acid (DCA) 86 and LCA. 6,28 87
In healthy humans administered ursodiol (15 mg/kg/day) for 3 weeks, biliary and 88 duodenal bile acid concentrations of UDCA and its conjugates (glycoursodeoxycholic 89 acid, GUDCA and tauroursodeoxycholic acid, TUDCA) increased by 40% compared to 90 baseline. 29 A decrease in primary bile acids (CA and CDCA) and their glycine and 91 taurine conjugates, as well as a decrease in the secondary bile acid DCA and its 92 conjugates (glycodeoxycholic acid, GDCA and taurodeoxycholic acid, TDCA) was 93 observed within biliary and duodenal bile. 29 An increase in conjugates of the secondary 94 bile acid LCA (glycolithocholic acid, GLCA and taurolithocholic acid, TLCA) were 95 observed after UDCA treatment within biliary and duodenal bile samples. 29 and Fiorucci et al. 4 ). Bile acids can also directly and indirectly, through activation of the 102 innate immune response, alter the gut microbial composition. 3, 4 Together, highlighting 103 the interconnectedness and complexity of the gut microbiota-bile acid-host axis, and 104 emphasizing the fact that exogenously administered bile acids will likely modulate this 105 axis. Our rudimentary knowledge of how ursodiol modulates the gut microbial 106 community structure, bile acid pool, and host physiology warrants further 107 at three distinct doses (50, 150, and 450 mg/kg dissolved in corn oil; Ursodiol U.S.P., 140
Spectrum Chemical, CAS 128-13-2) given daily via oral gavage for 21 days (Figure 1 ). 141
Ursodiol dosing was adjusted once weekly, based on current weight. Two independent 142 experiments were performed, with a total of n=8 mice (female/male) per treatment 143 group. Mice were weighed daily over the course of the experiment. Fecal pellets were 144 collected twice daily, flash-frozen and stored at -80°C until further analysis. A control 145 group of mice were necropsied prior to initiating any treatments (pretreatment group). 146
Necropsy was performed at day 21 in all Ursodiol treated mice. Gastrointestinal 147 contents and tissue from the ileum and cecum were collected, flash frozen in liquid 148 nitrogen, and stored at -80°C until further analysis. Serum and bile aspirated from the 149 gallbladder was obtained flash frozen in liquid nitrogen, and stored at -80°C until further 150
analysis. 151
On several occasions, mice had evidence of corn oil within the oral cavity or on their 152 muzzles immediately after the gavage. These mice were monitored closely for signs of 153 8 aspiration pneumonia for 36 hr following this event. Two mice, one from the Ursodiol 50 154 mg/kg group and another from the Ursodiol 450 mg/kg group, inadvertently aspirated 155 gavaged Ursodiol, containing corn oil, and subsequently developed respiratory distress 156 within 12-24 hr following the aspiration event. The clinical signs were most consistent 157 with lipid induced pneumonitis and both mice were humanely euthanized and excluded 158 from the study. 159
Targeted metabolomics of murine bile acid by UPLC-MS/MS. 160
Targeted analysis of bile acids in ileal and cecal content, fecal pellets, serum, and bile 161 were performed with an ACQUITY ultraperformance liquid-chromatography (UPLC) 162 system using a C8 BEH column (2.1 × 100 mm, 1.7 µm) coupled with a Xevo TQ-S 163 triplequadrupole mass spectrometer equipped with an electrospray ionization (ESI) 164 source operating in negative ionization mode (All Waters, Milford, MA) as previously 165 described. 30 The sample was thawed on ice and 25 mg was added to 1 mL of pre- (Updated  versions  of  this  protocol  can  be  found  at  223 http://www.mothur.org/wiki/MiSeq_SOP.) Custom read 1, read 2, and index primers 224 were added to the reagent cartridge, and FASTQ files were generated for paired-end 225 reads. 226
Microbiome analysis. 227
Analysis of the V4 region of the 16S rRNA gene was done using mothur (version 228 1.40.1). 32, 33 Briefly, the standard operating procedure (SOP) at 229 http://www.mothur.org/wiki/MiSeq_SOP was followed to process the MiSeq data. The 230 paired-end reads were assembled into contigs and then aligned to the SILVA 16S rRNA 231 sequence database (release 132) 34,35 and were classified to the mothur-adapted RDP 232 training set v16 36 using the Wang method and an 80% bootstrap minimum to the family 233 taxonomic level. All samples with <500 sequences were removed. Chimeric sequences 234 were removed using UCHIME. 37 Sequences were clustered into operational taxonomic 235 units (OTU) using a 3% species-level definition. The OTU data were then filtered to 236 include only those OTU that made up 1% or more of the total sequences. The 237 percentage of relative abundance of bacterial phyla and family members in each sample 238 was calculated. A cutoff of 0.03 (97%) was used to define operational taxonomic units 239 (OTU) and Yue and Clayton dissimilarity metric (θYC) was utilized to assess beta 240 diversity. In addition to NMDS ordination, principle coordinate analysis (PCoA) biplots 241 using Spearman correlation were used to examine difference in microbial community 242 structures between Ursodiol treatments and compared to pretreatment. Standard Paired fecal samples were collected from the same mice serially over the 21-day 279 experiment to facilitate simultaneous evaluation of the microbial community structure 280 and bile acid metabolome. Mice were sacrificed at day 21 and gut content from the 281 ileum and cecum were collected at necropsy, and stored for later analysis. 16S rRNA 282 gene sequencing was performed to define the gut microbiota. 283
Within the ileum, the gut microbial community structure of the Ursodiol 150 and 284
Ursodiol 450 treatment groups were significantly different from pretreatment ( Figure 3A ; 285 AMOVA; p = 0.02 and p = 0.009, respectively). Bar plots were utilized to visualize 286 relative composition of ileal microbial communities, which are different across each 287
Ursodiol dose and compared to pretreatment ( Figure 3C ). However, the overall gut 288 microbial community structure between treatments was not significantly different based Within the cecum, the gut microbial community structure of the Ursodiol 450 294 treatment group was significantly different from pretreatment ( Figure 3B ; AMOVA; p = 295 0.002). Bar plots were utilized to visualize relative composition of cecal microbial 296 communities, which were marginally different across each Ursodiol dose and compared 297 to pretreatment ( Figure 3D ). In accordance, the overall gut microbial community 298 structure between treatments was not significantly different based on AMOVA. A biplot 299 of the top 10 OTUs towards PCoA axes 1 and 2 revealed OTU 86 (classified as 300 Lachnospiraceae) as a significant member contributing to cecal microbial community 301 alterations seen with Ursodiol treatment ( Figure S1B) . To determine the extent that ursodiol alters the bile acid pool, assessment of 47 bile 311 acids, was conducted on paired ileal, cecal, and fecal samples used in the preceding 312 microbial community structure evaluation. In addition to NMDS ordination and 313 comprehensive bile acid profile heatmaps, Random Forest analysis was applied to 314 identify bile acids that are important for distinguishing between ursodiol treatments. 315
Ileal content bile acid profiles revealed segregation of the ursodiol 150 and 316 ursodiol 450 treatments from pretreatment bile acid profiles ( Figure 4A ). A total of 35 317 distinct bile acids were quantified within murine ileal content ( Figure 4C ). When 318 assessing the ileal bile acid profile, 3 bile acids, TUDCA, tauro-β-muricholic acid 319 (TβMCA), and TCA were significantly different compared to pretreatment using a two-320 way ANOVA followed by Dunnett's multiple comparisons post hoc test. For TUDCA, all 321 three ursodiol treatments were significantly different from pretreatment (all treatments, p 322 = 0.0001). For TβMCA, only the ursodiol 50 treatment was significantly different from 323 pretreatment (p = 0.0001). For TCA, all three ursodiol treatments were significantly 324 different from pretreatment (Ursodiol 50, p = 0.0002; Ursodiol 150, p = 0.0040, and 325
Ursodiol 450, p = 0.0374). Within the ileal content, the two highest MDA scores from the 326 Random Forest analysis were UDCA and TUDCA, with high concentrations of both 327 these bile acids in the ursodiol 450 treatment group ( Figure S2A) . A Kruskal-Wallis one-328 way ANOVA test followed by Dunn's multiple comparisons test was used to calculate 329 the significance of an individual bile acid within each Ursodiol treatment group 330 compared to pretreatment. For ileal content, UDCA, TUDCA, GUDCA, and LCA were 331 significantly higher in ursodiol 450 treatment compared to pretreatment (p = 0.0007, p = 332 0.0013, p = 0.0022, and p = 0.0218, respectively; Figure S3A ). 333
Cecal content bile acid profiles revealed segregation of the ursodiol treatments 334 from pretreatment bile acid profiles ( Figure 4B ). A total of 38 distinct bile acids were 335 quantified within murine cecal content ( Figure 4D ). When assessing the cecal bile acid 336 profile, 2 bile acids, TUDCA and TβMCA were significantly different compared to 337 pretreatment using a two-way ANOVA followed by Dunnett's multiple comparisons post 338 hoc test. For TUDCA, Ursodiol 50 and 450 treatment groups were significantly different 339 from pretreatment (both treatments, p = 0.0001). For TβMCA, only the Ursodiol 50 340 treatment was significantly different from pretreatment (p = 0.0219). The two highest 341 compared to pretreatment (p = 0.0143, p = 0.0255; and p = 0.0280, respectively; 348
Figures S3B). UDCA, TUDCA, GUDCA, TβMCA, and MCA were significantly higher in 349 the Ursodiol 450 treatment compared to pretreatment (p = 0.0.0307, p = 0.0047, p = 350 0.0160, p = 0.0352, and p = 0.0321, respectively; Figures S3B) . significantly different from pretreatment only at Day 8 (p = 0.0296 and p = 0.0001, 359 respectively). Within the Ursodiol 150 treatment group, UDCA and TUDCA were 360 significantly different from pretreatment only at Day 15 (p = 0.0001 and p = 0.0107, 361 respectively). Within the Ursodiol 450 treatment group, UDCA was significantly different 362 from pretreatment at Days 5 (p =0.0020), 8 (p = 0.0007), 10 (p = 0.0044), and 15 (p = 363 0.0001). TUDCA was also significantly different from pretreatment in the Ursodiol 450 364 group at all sampling days (p = 0.0001 for all days). Additionally, MCA and TβMCA in 365
the Ursodiol 450 treatment group on Day 15 were significantly different from 366 pretreatment (p = 0.0001 for both). test was used to calculate the significance of an individual bile acid within each Ursodiol 375 treatment group compared to pretreatment. UDCA, TUDCA, GUDCA, and LCA were 376 significantly higher in Ursodiol 450 treatment compared to pretreatment (p = 0.0008, p = 377 0.0007, p = 0.0230, and p = 0.0065, respectively; Figure S4D) . 378
Discussion 379
This study is the first to provide a comprehensive examination of how exogenously and affinity for FXR and TGR5 (see Table 1 ). This intensifies the complexity of Acquisition of such data, in combination with the comprehensive microbiome and bile 421 acid metabolome data obtained in this study, could be integrated using bioinformatics 422 and mathematical modeling to further illustrate these intricate interactions between the 423 gut microbiota, bile acids, and the host in an Ursodiol altered intestinal ecosystem. 424
During ursodiol administration significant weight loss was noted in the ursodiol 50 425
and Ursodiol 450 treatments compared to untreated mice (Figure 2 ). We speculate that 
